Health Economics›Chronic lymphocytic leukemia›First-line therapy, non-randomized or retrospective data

First-line therapy, non-randomized or retrospective data

Chronic lymphocytic leukemia · 1 regimen

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Ibrutinib, Venetoclax, Obinutuzumab Variant #01	—	R 295 786	28d	—	—	14	R 2 457 326 PFS proxy	2

1 of 1 regimen shown